Abzena is a San Diego CDMO focused on drug substance and fill-finish manufacturing. The company is led by CEO Jonathan Goldman. It secured a $65 million investment to expand its manufacturing capacity. Abzena committed a portion of that investment to build out operations in the hot North Carolina scene. The capital is earmarked to grow drug substance and fill-finish capabilities. The article does not disclose operating metrics, past rounds, or additional financial details. Abzena is a Cambridge, UK-based global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody-drug conjugates (ADCs). Led by Jonathan Goldman, MD, the company offers integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing services. Abzena maintains resources around the world, with facilities in the US and UK. The company raised $10M in growth funding from Biospring Partners. Abzena intends to use the new capital to accelerate its growth plans.

Total raised

$75M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2022